Payment overview · 2025
General Payments
$128.39
7 reported records · 3 companies
Healthcare provider profile · identity verified
Sandra A Pike, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · OSWEGO, NY · NPI 1255598868
Verified facts
What the public records show
CMS Open Payments records show Sandra A Pike, NP received $128.39 in general payments during 2025 across 7 reported records.
AstraZeneca Pharmaceuticals LP accounted for 36.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $46.52 | 36.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $42.13 | 32.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $39.74 | 30.9% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $128.39 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $42.13 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $39.74 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $31.02 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 76 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
20 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
76 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 373 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 306 | 83 |
| Lisinopril | Lisinopril | 276 | 87 |
| Omeprazole | Omeprazole | 230 | 66 |
| Losartan Potassium | Losartan Potassium | 224 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 205 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 203 | 60 |
| Simvastatin | Simvastatin | 187 | 50 |
| Alprazolam | Alprazolam | 178 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 147 | 46 |
| Famotidine | Famotidine | 136 | 50 |
| Metformin Hcl Er | Metformin Hcl | 130 | 39 |
| Sertraline Hcl | Sertraline Hcl | 120 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 115 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 114 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 114 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 107 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 107 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 32 |
| Allopurinol | Allopurinol | 98 | 30 |
| Meloxicam | Meloxicam | 95 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 92 | 16 |
| Montelukast Sodium | Montelukast Sodium | 91 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 87 | 27 |
| Metformin Hcl | Metformin Hcl | 87 | 29 |
| Torsemide | Torsemide | 82 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 78 | 23 |
| Prednisone | Prednisone | 78 | 51 |
| Tramadol Hcl | Tramadol Hcl | 77 | 24 |
| Glimepiride | Glimepiride | 76 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 76 | 22 |
| Buspirone Hcl | Buspirone Hcl | 73 | 18 |
| Eliquis | Apixaban | 70 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 15 |
| Azithromycin | Azithromycin | 63 | 52 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 61 | 21 |
| Potassium Chloride | Potassium Chloride | 59 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 18 |
| Bupropion Xl | Bupropion Hcl | 56 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 19 |
| Gabapentin | Gabapentin | 53 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 18 |
| Furosemide | Furosemide | 45 | 15 |
| Carvedilol | Carvedilol | 43 | 14 |
| Finasteride | Finasteride | 42 | 11 |
| Estradiol | Estradiol | 41 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 34 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 15 |
| Donepezil Hcl | Donepezil Hcl | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Lorazepam | Lorazepam | 35 | suppressed |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Lovastatin | Lovastatin | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 23 |
| Vascepa | Icosapent Ethyl | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 26 |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Spironolactone | Spironolactone | 29 | 11 |
| Azelastine Hcl | Azelastine Hcl | 28 | suppressed |
| Ezetimibe | Ezetimibe | 28 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 27 |
| Nystatin | Nystatin | 28 | 14 |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Oxycontin | Oxycodone Hcl | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 15 |
| Glipizide | Glipizide | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 18 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 17 |
| Clonazepam | Clonazepam | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 11 |
| Ozempic | Semaglutide | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 13 | suppressed |
| Exemestane | Exemestane | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $128.39 · 7 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, TRELEGY ELLIPTA, UBRELVY | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error